SGHT · Sight Sciences, Inc.
$5.12
+0.19 (+3.85%)
At close · Jul 27
Market Cap
$278.58M
Shares
54.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.12
Open$5.00
Day$4.99–5.23
52W$3.11–9.24
Avg vol 30d183K
Short int830K · 1.5% float · 5.0d
Short vol31%
Last earningsAug 5, 2026
DataJul 2021–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Scheduled
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
+1%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
33%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−18%
trailing
YTD return
−35%
this year
Relative strength
−25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Distributing
15 of 113 funds reported for Jun 30 · net -71.9K sh shares · +3 new
Insider flow
Accumulating
Net +$3.6K over 90 days · 50% sells
Short interest
Rising
1.53% of float · ▲ +14.2% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
113 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
Gross margin
86%
expanding
EPS growth
+28%
Y/Y
Free cash flow
$-29.9M
Balance sheet
$51.7M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
full year 2026
Total revenue
Initiated
$82M – $88M
prior FY $77.36M
midpoint +9.9% Y/Y
Interventional Glaucoma revenue
Initiated
$77M – $81M
Interventional Dry Eye revenue
Initiated
$5M – $7M
Adjusted operating expenses
Non-GAAP
Initiated
$93M – $96M
first quarter 2026
Interventional Dry Eye revenue
Initiated
$1M
Guided vs delivered
· last 1 settled
Revenue
full year 2025
guided $76M – $78M
$77.36M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
33%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Distributing
15 of 113 funds reported for Jun 30 · net -71.9K sh shares · +3 new
Insider flow
Accumulating
Net +$3.6K over 90 days · 50% sells
Short interest
Rising
1.53% of float · ▲ +14.2% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
113 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $5 · 33%
52-wk high $9
vs 200-day avg -7%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted operating expenses non-GAAP | $21.2M | the first quarter of 2026 | — |
|
|
|||
| Interventional Dry Eye gross margin | 72% | the first quarter of 2026 | — |
| Interventional Glaucoma gross margin | 87% | the first quarter of 2026 | — |
| Interventional Dry Eye active customers | 81 | Three Months Ended December 31, 2025 | — |
| Interventional Dry Eye lid treatment units sold | 713 | Three Months Ended December 31, 2025 | — |
| Interventional Glaucoma active customers | 1,164 | Three Months Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGHT
this stock
Sight Sciences, Inc.
|
$278.58M | -35.4% | -3.1% | — | 1.5% |
|
ABT
Abbott Laboratories
|
$182.00B | -16.2% | +5.7% | 29.3 | 1.4% |
|
SYK
Stryker Corp
|
$126.60B | -3.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$106.51B | -11.6% | +8.4% | 22.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.77B | -52.3% | +5.5% | 18.5 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGHT | +1.8% | -6.2% | -18.5% | -5.5% | -35.4% |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | +2.4% | -6.9% | -25.3% | -4.5% | -43.8% |
Key facts
CIK
1531177
CUSIP
82657M105
13F (30d)
14 filings
14 filers
Visit website
Investor relations